Plague vaccine - PharmAtheneAlternative Names: Recombinant Yersinia pestis vaccine - PharmAthene; Recombinant dual antigen vaccine for plague - PharmAthene; rYP vaccine - PharmAthene; RypVax
Latest Information Update: 27 May 2010
At a glance
- Originator Avecia
- Developer PharmAthene
- Class Plague vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Suspended Plague
Most Recent Events
- 08 Oct 2004 Preclinical trials in Pneumonic plague in United Kingdom (Parenteral)